Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 2

1(33.3%)

Phase 3

1(33.3%)

3Total

N/A(1)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05453721Not ApplicableCompleted

Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane（IMPLANE-0529）

Role: collaborator

NCT05001971Phase 2Completed

Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy

Role: collaborator

NCT02623556Phase 3Completed

Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

Role: collaborator

NCT02503449Unknown

Clinical Trial of Pulmonary Cryptococcosis in China

Role: collaborator

NCT01337037Unknown

Modified Video-assisted Thoracoscopic Surgery (VATS) Lobectomy for Early-stage Non-small Cell Lung Cancer (NSCLC)

Role: collaborator

All 5 trials loaded